PP2A-activating drugs reduced the survival and self-renewal of quiescent CML LSCs—but not normal HSCs—through inhibition of JAK2 and β-catenin via a mechanism independent of BCR-ABL138. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.